The Genome Institute of Singapore
Recognized as a top breast cancer researcher, Edison Liu was a pioneer in using mutations in the cancer-associated ras gene to study different types of the disease. His gene-discovery approaches identified a number of novel kinases involved in breast cancer that turned out to be significant. His recent work centers on the expression genomics of human cancers and the use of transcription genetics in deciphering cryptic signaling pathways.
While at the University of North Carolina at Chapel Hill, Dr. Liu developed leukemia and breast cancer research programs, directed the Specialized Program of Research Excellence (SPORE) in Breast Cancer, led the Breast Cancer Program at the Lineberger Comprehensive Cancer Center, and served as Chief of the Division of Medical Genetics at the School of Medicine. In 1996, he became the National Cancer Institute's director of the Division of Clinical Sciences. Currently he is building an international research institute in Singapore focused on integrating genomic sciences with cell and medical biology.
Dr. Liu has received many awards, including the Brinker International Award and the Rosenthal Award from the American Association for Cancer Research. He belongs to the American Federation for Clinical Research, the American Association for the Advancement of Science, the American Society of Hematology, and the American Society for Clinical Investigation and has sat on many advisory boards here and in Singapore. He is executive editor of the journal Breast Disease and has served on the editorial boards and advises several other journals. He has contributed more than 130 papers and reviews to the literature.
Dr. Liu earned his degrees from Stanford University.